Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

Abstract Background The anti–interleukin-6 receptor-alpha antibody tocilizumab was approved for intravenous (IV) injection in the treatment of patients with systemic juvenile idiopathic arthritis (sJIA) aged 2 to 17 years based on results of a randomized controlled phase 3 trial. Tocilizumab treatme...

Full description

Bibliographic Details
Main Authors: Navita L. Mallalieu, Sunethra Wimalasundera, Joy C. Hsu, Wendy Douglass, Chris Wells, Inmaculada Calvo Penades, Ruben Cuttica, Hans-Iko Huppertz, Rik Joos, Yukiko Kimura, Diana Milojevic, Margalit Rosenkranz, Kenneth Schikler, Tamas Constantin, Carine Wouters
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Biological therapy
Inflammation
Juvenile idiopathic arthritis
Pharmacokinetics
Online Access:http://link.springer.com/article/10.1186/s12969-019-0364-z

Internet

http://link.springer.com/article/10.1186/s12969-019-0364-z

Similar Items